Products & Services

Our Solutions

We have developed products for Alzheimer’s disease (AD) diagnosis and treatment based on the cell division cycle theory of AD pathogenesis.

Our products address the unmet needs for early diagnosis–before irreversible brain degeneration, and eventually symptoms, occur–and for new treatment strategies. Our cellular (lymphocyte) and genetic assays are used sequentially to identify cell cycle deficits in patients who are in presymptomatic stages of dementia. Our lymphocyte test is performed first in order to establish the presence of an AD-type G1/S cell cycle regulatory deficit. Our genetic tests are then used to determine the patient’s particular G1/S deficit based on specific mutations in cyclin-dependent kinase inhibitor (CDKI) genes.

Because our assays target early markers and identify pathological causes (i.e., cell cycle deficits) of AD, they are also powerful tools for informing R&D of disease-modifying treatment strategies. Our lead drug screen tests compounds for disease-modifying potential in AD. Our assays offer unique opportunities for drug and diagnostic companies in all phases of AD product and market development, from discovery and preclinical R&D to marketed products.